ReviewTrends in biotechnology2017
Engineered Liver Platforms for Different Phases of Drug Development.
Review in Trends in biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 86 citations in OpenAlex.
- A Dynamic 3D Human Liver Sinusoid Model for Mechanistic Interrogation of Fontan-Associated Liver Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cell-embedded microgels as emerging miniature 3D tissue-mimics toward biochip-based toxicity screening.Bioengineering & translational medicine · 2026Review
- Spatial patterning strategies for liver tissue engineering: Biofabrication technologies and applications.Advanced drug delivery reviews · 2026Review
- Alternatives to animal models in gastroenterology and hepatology research.Frontiers in pharmacology · 2026Review
- From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases.Advances in pharmacological and pharmaceutical sciences · 2025Review
- Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Organ-on-a-Chip:Pharmaceutics · 2024Article
- Review
- Mechanistic Understanding of Idiosyncratic Drug-Induced Hepatotoxicity Using Co-Cultures of Hepatocytes and Macrophages.Antioxidants (Basel, Switzerland) · 2023Article
- Estimating Hepatotoxic Doses Using High-Content Imaging in Primary Hepatocytes.Toxicological sciences : an official journal of the Society of Toxicology · 2021Article
- Development of a Hybrid Polymer-Based Microfluidic Platform for Culturing Hepatocytes towards Liver-on-a-Chip Applications.Polymers · 2021Article
- Liver-Heart on chip models for drug safety.APL bioengineering · 2021Review
- Development of improved SRC-3 inhibitors as breast cancer therapeutic agents.Endocrine-related cancer · 2021Article
- A versatile microfluidic tool for the 3D culture of HepaRG cells seeded at various stages of differentiation.Scientific reports · 2021Article
- Investigations on T cell transmigration in a human skin-on-chip (SoC) model.Lab on a chip · 2021Article
- Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine.Bioactive materials · 2021Review
- Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies.Pharmaceutics · 2020Review
- Multicellular Systems to Translate Somatic Cell Genome Editors to Humans.Current opinion in biomedical engineering · 2020Article
- A liver-on-a-chip for hepatoprotective activity assessment.Biomicrofluidics · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Drug-induced liver injury (DILI) remains a leading cause of drug withdrawal from human clinical trials or the marketplace. Owing to species-specific differences in liver pathways, predicting human-relevant DILI using in vitro human liver models is crucial. Microfabrication tools allow precise control over the cellular microenvironment towards stabilizing liver functions for weeks. These tools are used to engineer human liver models with different complexities and throughput using cell lines, primary cells, and stem cell-derived hepatocytes. Including multiple human liver cell types can mimic cell-cell interactions in specific types of DILI. Finally, organ-on-a-chip models demonstrate how drug metabolism in the liver affects multi-organ toxicities. In this review we survey engineered human liver platforms within the needs of different phases of drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.